


Pathways of economic impact arising from MRC-funded research



Professor Patrick Chinnery
MRC Executive Chair

Medical Research Council (MRC) funded discovery science has pushed the frontiers of biomedical knowledge whilst driving economic growth and advancing human health.

Our own funding schemes have accelerated the translation of our discoveries in close partnership with:

- National Institute for Health and Care Research (NIHR)
- medical charities and
- the commercial sector

MRC has empowered a large proportion of UK spin-outs in the biomedical sector, and **every £1 we invested** through our translational schemes has **leveraged £5.3 from industry.**

A powerful benefit for the UK economy arises from the **increased longevity and productivity** of the population resulting from new health interventions. Informing health policy, as well as the development of more cost-effective therapies that lower NHS expenditure also provide significant benefits for the UK economy.

Our successes have flourished across the UK, contributing to local prosperity through the creation of **new jobs.**

We are proud of what we have achieved over the last decade, and based on our track record, we're confident that MRC will make an even stronger contribution to UK growth in the years to come, addressing major health needs in our ageing society.

Economic impacts

Product sales

Sales

Sales of **£258 billion** from the two globally best-selling therapeutics of the hundreds of products arising from MRC-funded research


Two spin-outs currently generating over **£100 million** in revenues per annum, despite only recently receiving marketing authorisation

Investment in spin-outs

Inward investment

Attracting more than **£10 billion** in external investment

Currently **296** active spin-outs



Attracting **34 percent** of all UK investment in biomedical spin-outs launched 2008-2023

Sale of spin-outs

Spin-out sales

Mergers and acquisitions of spin-out arising from MRC-funded research more than **£3.7 billion**

Jobs

Jobs

5,400 Jobs created from all known spin-outs linked to MRC-funded research

Creating successful non-therapeutic businesses

Spillover technologies

CDMOs and CROs* providing manufacturing and research services to the pharmaceutical sector'

Creating a healthy workforce

Healthy population

Supporting a productive, healthy population

Prostate cancer treatment resulting in

31,250 extra life years for UK patients

£25 billion

benefit to the UK government through improved lives through revised tobacco packaging

More efficient therapy protocols saving time for UK patients, recovering **£8 million**

each year in lost work hours

More economically efficient NHS


More efficient technologies

Enhanced stroke diagnosis saving NHS **£200 million** per year

Revised blood clot management saving NHS **£140 million** over 20 years

* Contract Development and Manufacturing Organisation and Contract Research Organisation

MRC's successful translational funding



Spin-outs linked to MRC translational research

146 new companies



Quotes from independent Ipsos Mori report*



Effective translation “benefited from funding through MRC’s dedicated translational research programme – allowing researchers to progress the development of the relevant assets further prior to the formation of an external commercial vehicle (in some cases as far as early clinical trials).”



While the high level of investment in the continuing pipeline of spin-outs arising from MRC funded research since 2008 shows promise of great economic impact in the future, the timelag between breakthrough and clinic has meant that the profits have yet to be realized. Spin-outs pre-2008 demonstrate the sales impact that can develop from research break throughs as well as the growth of UK companies and their job creation.

* Ipsos Mori: Development and growth of spin-outs from MRC research report